<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02127437</url>
  </required_header>
  <id_info>
    <org_study_id>LIPS-01</org_study_id>
    <nct_id>NCT02127437</nct_id>
  </id_info>
  <brief_title>Lanreotide In Polycystic Kidney Disease Study</brief_title>
  <acronym>LIPS</acronym>
  <official_title>Lanreotide In Polycystic Kidney Disease Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IPSEN pharmaceutical company, Boulogne-Billancourt, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      LIPS study (Lanreotide In Polycystic kidney disease Study) is a prospective randomized double
      blind placebo controlled study. The main objective is to prove that lanreotide, a
      somatostatin analog, is able to reduce the glomerular filtration rate decline over 3 years by
      at least 30%. Cardiovascular outcomes, blood pressure, quality of life and safety are among
      the secondary outcomes. The study, which will include 180 ADPKD patients, is scheduled to
      start in early 2014.

      An equal number of patients with chronic kidney disease stage 2 (90 patients with GFR 89 to
      60 ml/mn/1.73 m2) and chronic kidney disease stage 3 (90 patients with GFR 59 to 30
      ml/mn/1.73 m2) will be included. The primary endpoint (GFR decline) will be assessed by
      repeated measures, in the overall population as well as in the two GFR stratus.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 19, 2014</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glomerular filtration rate (GFR)</measure>
    <time_frame>month 36</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtration rate (GFR)</measure>
    <time_frame>month 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtration rate (GFR) decline</measure>
    <time_frame>month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety, tolerance</measure>
    <time_frame>month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset or worsening of hypertension</measure>
    <time_frame>month 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset or worsening of hypertension</measure>
    <time_frame>month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>month 0</time_frame>
    <description>SF-36, EQ5D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>month 18</time_frame>
    <description>SF-36, EQ5D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>month 36</time_frame>
    <description>SF-36, EQ5D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cystic pain</measure>
    <time_frame>month 36</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">156</enrollment>
  <condition>Autosomal Dominant Polycystic Kidney Disease (ADPKD</condition>
  <arm_group>
    <arm_group_label>A - treated group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B - control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanreotide</intervention_name>
    <description>120 mg, subcutaneously, once every 4 weeks</description>
    <arm_group_label>A - treated group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>0,5 ml, subcutaneously, once every 4 weeks</description>
    <arm_group_label>B - control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  autosomal dominant polycystic kidney disease (clinical, familial, imaging grounds)

          -  measured GFR : 30 to 89 ml/mn/1.73m2

          -  age &gt; 18

          -  affiliated with health insurance

          -  written informed consent

        Exclusion Criteria:

          -  iohexol /iodine allergy

          -  diabetes mellitus

          -  other associated nephropathy suspected

          -  evolutive or recent malignant disease ( in the previous 5 years)

          -  cholelithiasis

          -  uncontrolled hypertension (BP&gt;160/100 mmHg)

          -  cardiac failure of grade III or IV according to the NYHA (New York Heart Association)
             classification

          -  liver failure

          -  psychiatric illness

          -  pregnancy, lactation, lack of contraception

          -  use of somatostatin analogs during the last 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominique JOLY, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Necker hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Necker hospital</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2014</study_first_submitted>
  <study_first_submitted_qc>April 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2014</study_first_posted>
  <last_update_submitted>December 20, 2017</last_update_submitted>
  <last_update_submitted_qc>December 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autosomal dominant polycystic kidney disease,</keyword>
  <keyword>Glomerular filtration rate,</keyword>
  <keyword>Somatostatin,</keyword>
  <keyword>lanreotide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lanreotide</mesh_term>
    <mesh_term>Angiopeptin</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

